PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients

Conclusion: This study indicates the safety and significant efficiency of GRPR antagonist 68Ga-RM26. 68Ga-RM26 PET/CT would have remarkable value in detecting both primary prostate cancer and metastasis. 68Ga-RM26 is also expected to be better than GRPR agonist as an imaging marker to evaluate GRPR expression in prostate cancer.

Source: Journal of Nuclear Medicine - June 1, 2018 Category: Nuclear Medicine Authors: Zhang, J., Niu, G., Fan, X., Lang, L., Hou, G., Chen, L., Wu, H., Zhu, Z., Li, F., Chen, X. Tags: Clinical Source Type: research